NewEdge Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

NewEdge Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5	Closed	-$40	–	4100
2025 Q2	$40	Sell	5 -38	-88%	-$286	﹤0.01%	3939
2025 Q1	$360	Hold	43	–	–	﹤0.01%	3751
2024 Q4	$341	Buy	+43	New	+$361	﹤0.01%	3707

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

NewEdge Advisors's AMRX Position: Q3 2025 in Review

NewEdge Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 5 shares — an estimated $40 sold.

NewEdge Advisors first reported a position in AMRX in Q4 2024 and held it in 3 quarters. The position peaked at $360 in Q1 2025. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

NewEdge Advisors reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
NewEdge Advisors sold 5 Amneal Pharmaceuticals shares in Q3 2025, an estimated $40.
NewEdge Advisors first reported a position in Amneal Pharmaceuticals in Q4 2024 and held it in 3 quarters.
NewEdge Advisors's Amneal Pharmaceuticals position peaked at $360 in Q1 2025.
248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.